AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00880230 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scuba Iliac Stent System
Description: The Scuba™ Stent System consists of a balloon-expandable stent and an over the wire (OTW) delivery system.
Study NCT03430895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: durvalumab and tremelimumab
Description: Patients will receive durvalumab 1500 mg and tremelimumab 75 mg IV Q4W for up to 4 doses/cycles, then durvalumab 1500 mg Q4W starting 4 weeks after the last combination treatment for up to 9 doses.
Study NCT01803503 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 75mg/m2 day 1, every 3 weeks
Study NCT01803503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75mg/m2 day 1, every 3 weeks
Study NCT01803503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: 7 days of sunitinib 12.5mg orally daily during each cycle
Study NCT04441840 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Active Probiotic Culture
Description: Both conditions matched in appearance and serving size
Study NCT01127906 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo suspension
Description: Oral Placebo suspension (matched to PF-04531083 suspension)
Study NCT01127906 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo tablet
Description: Oral Placebo tablet (matched to Oxycodone)
Study NCT01127906 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oxycodone 20mg
Description: Oral Oxycodone 20mg (Oxycontin) controlled release formulation
Study NCT02440594 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced BHL Program Services
Description: Patients or their caregivers will work with a BHP to provided additional support and education beyond the services received in the Standard BHL Program.
Study NCT02440594 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard BHL Program Services
Description: Patients or their caregivers receive a baseline clinical assessment as well as monitoring of symptoms and referral to community resources.
Study NCT03810313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brolucizumab 6 mg
Description: Solution for injection (intravitreal use)
Study NCT03810313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept 2 mg
Description: Solution for injection (Intravitreal use)
Study NCT04441840 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Inactive Probiotic Culture
Description: Both conditions matched in appearance and serving size
Study NCT04250532 — intervention group
Intervention type: OTHER
Intervention: Drowning
Description: Measurement of pulse oximetry, after lifeguard immersion during their morning training
Study NCT00059605 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DOTAP:Chol-fus1
Description: Infusion of DOTAP:Chol-fus1 by vein once every 3 weeks.
Study NCT03385304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10% povidone-iodine (1% free iodine) in purified water
Description: Participant recruitment will begin with the clinical sites using their assigned pre-operative antiseptic skin solution for all open fracture surgeries for a two-month period.
Study NCT03385304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4% chlorhexidine gluconate (CHG) in purified water
Description: Once the first intervention phase is completed, each site will crossover to the opposite study solution. Each site will need to develop local procedures to ensure a successful crossover. They will use the second solution for all open fracture surgeries for a two-month period, and will then crossover back to the solution in the first intervention phase.
Study NCT02832375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: stannous fluoride
Description: 0.454% w/w stannous fluoride containing 1100ppm of fluoride
Study NCT02832375 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium monofluorophosphate
Description: 0.76% w/w sodium monofluorophosphate containing 1000ppm fluoride
Study NCT02075528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Description: 9 mg/d of paliperidone ER was administered during the first 2 weeks, after which the dose was adjusted clinically
Study NCT03589976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus 2 MG
Description: Dose will be adjusted throughout this trial based on sirolimus plasma levels and the presence of drug-related adverse events. The maximum dose will be 6mg/day.
Study NCT03589976 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients receiving placebo will undergo analog sham level measurements and the number of tablets will be also adjusted to maintain the blinding of the trial.
Study NCT01565668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC220
Description: oral
Study NCT03018496 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta-Hydroxy-Beta-Methylbutyrate
Study NCT03018496 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT03966924 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rotational fractional resection (1.5mm Diameter Device)
Description: Single treatment of skin resection and with and without focal lipectomy (removal of loose skin and fat)
Study NCT01168908 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sildenafil
Description: 20mg tablet three times daily
Study NCT01168908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: 20mg tablet three times daily
Study NCT03216590 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compressive draping using adhesive incise drape
Description: In the intervention group the shoulder will be drape with compressive draping using adhesive incise drape (Ioban™2 Antimicrobial Incise Drape, 3M Inc.,USA).
Study NCT03810313 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham injection
Description: Empty sterile syringe without a needle administered as a sham injection for masking. From Week 24 to Week 72 inclusive, a sham treatment was performed to maintain subject masking in case treatment with brolucizumab or aflibercept was not deemed necessary by the investigator.
Study NCT03810313 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham injection
Description: Empty sterile syringe without a needle administered as a sham injection for masking. From Week 24 to Week 72 inclusive, a sham treatment was performed to maintain subject masking in case treatment with brolucizumab or aflibercept was not deemed necessary by the investigator.
Study NCT02861326 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Gracey Curettes
Study NCT00453531 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Limb Ischemia
Study NCT00453531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcholine
Study NCT02668809 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: oral health assessment
Description: A baseline oral health assessment of both residents and direct care workers will be conducted before interventions are initiated. Data will be entered directly into a spreadsheet format using the chairside software program to be developed as part of this proposal.
Study NCT02668809 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral health assessment
Description: A baseline oral health assessment of both residents and direct care workers will be conducted before interventions are initiated. Data will be entered directly into a spreadsheet format using the chairside software program to be developed as part of this proposal.
Study NCT02668809 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaires
Description: Age, sex, race, nutrition (mini-nutri), quality of life (SF-36), OHIP-14, GOHAI, sources of payment for the NF residency, comorbid conditions (e.g., constipation, arthritis), weight, medications, cognitive status (mini-mental) , dry mouth sensation, x-ray documented pneumonia;
Study NCT02668809 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Age, sex, race, nutrition (mini-nutri), quality of life (SF-36), OHIP-14, GOHAI, sources of payment for the NF residency, comorbid conditions (e.g., constipation, arthritis), weight, medications, cognitive status (mini-mental) , dry mouth sensation, x-ray documented pneumonia;
Study NCT02668809 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Clinical Exam
Description: Dentate status, dental/denture plaque index, DMFS (including root surfaces), gingival bleeding index, plaque index, presence of oral lesions, verification of mouth dryness;
Study NCT02668809 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Exam
Description: Dentate status, dental/denture plaque index, DMFS (including root surfaces), gingival bleeding index, plaque index, presence of oral lesions, verification of mouth dryness;
Study NCT02668809 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Microbiological sampling
Description: Samples will be collected by swabbing patients intra-oral tissues. Samples will be separately collected from dentures and oral tissues for edentulous patients, also using swabs. All samples will be suspended in saline solution.
Study NCT02668809 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Microbiological sampling
Description: Samples will be collected by swabbing patients intra-oral tissues. Samples will be separately collected from dentures and oral tissues for edentulous patients, also using swabs. All samples will be suspended in saline solution.
Study NCT02668809 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monitoring Adherence
Description: Adherence to the protocol will be evaluated through unannounced observations at the NF by study personnel twice per month. Adherence is determined by direct observation of the DCW administering the intervention.
Study NCT02668809 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Varnish application
Description: 1% chlorhexidine varnish application group will receive the educational program described above. In addition, residents who need supervision or are unable to perform oral hygiene procedures will receive 1% chlorhexidine varnish application monthly by the dental hygienist. No additional time commitment will be necessary.The direct care workers will NOT receive any varnish.
Study NCT02668809 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Consent
Description: Both the residents and primary care workers will be asked to participate on the study, and the investigators will provide information and collect signed informed consents primarily during two in person visits to each nursing facilities.
Study NCT02668809 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Consent
Description: Both the residents and primary care workers will be asked to participate on the study, and the investigators will provide information and collect signed informed consents primarily during two in person visits to each nursing facilities.
Study NCT02668809 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Program
Description: Cognitively capable residents will receive instruction on how to perform their own oral hygiene accordingly to their own needs; and 2) Direct care workers will receive instruction on how to perform oral hygiene for dependent residents or supervise the oral hygiene routines of independent patients. For both 1) and 2) above, dental hygienists will provide a short, standardized presentation and hands-on demonstration.
Study NCT03352193 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Wheat spaghetti
Description: Wheat oral immunotherapy
Study NCT04248140 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: radio frequency electromagnetic field
Description: Exposure system delivers emissions comparable to those from WiFi access point close to the bed or sham (nor exposure)
Study NCT04016922 — intervention group
Intervention type: OTHER
Intervention: Oral ferrous fumerate for Group A, Parenteral iron sucrose for Group B, Compatible blood transfusion for Group C
Description: Consent, history. US: fetal heart activity, placental site, fetal biometry, AFI, anomalies, Doppler: umbilical artery, MCA, fetal renal artery, C\\U ratio.~\* Maternal Hb,US at time of first visit, 10 days later after initiation of treatment, at EDD .~* As part of routine medical care of these patients, they are managed as:~A: give oral iron in the form of ferrous fumerate with the possible side effects. if Hb returns to normal, continue iron for 3 mon.~B: admit to receive IV iron sucrose according to product literature allergic reaction may happen; antiallergic measures. C: give blood transfusion in the form of packed RBC. allergic and pyrogenic reaction and infection may occur. At delivery will be subjected to: examination, investigations, US.
Study NCT02814786 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MRI scanner
Description: This examination is divided in 2 parts:~* Passive movement: after placing the ankle joint in the fixture, each child will be asked to relax the lower limb musculature and then the fixture will be cyclically moved by a technician at a speed which does not trigger spasticity.~* Active movement: no technician will be present and children will be asked to perform voluntary plantar-dorsiflexion between the extreme positions on the beat of the metronome.
Study NCT02814786 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait analysis
Description: For gait evaluation, each child will undergo a lower limb gait analysis in a motion analysis laboratory equipped with Camera system and 4 AMTI force plates Sixteen reflective markers will be placed on the lower limbs. Each child will walk bare foot and gait will be recorded during each of five 10-meter trials. A velocity of 1 m/s (+/- 10%) will be imposed using a stop watch in order to eliminate the influence of velocity on gait kinematics and kinematics while comparing across subjects. Each child will be allowed to walk for 5 minutes after attaching the reflective markers and before recording the gait data. In addition to the joint kinematics, joint powers and moments will be computed using an inverse dynamics method.
Study NCT03700333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1 therapy
Description: accept S-1(50mg, twice a day, morning and night, if\<1.5m2; 75mg, twice a day, morning and night,if >1.5m2 )chemotherapy after finishing first-line therapy(>21 days).
Study NCT03700333 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed therapy
Description: accept Pemetrexed (500mg/m2,d1)chemotherapy after finishing first-line therapy(>21 days).
Study NCT02372929 — intervention group
Intervention type: PROCEDURE
Intervention: Endoscopic Ultrasound
Description: Esophageal cancer patients will be staged by endoscopic ultrasound. All patients will undergo upper endoscopy prior to endoscopic ultrasound.
Study NCT03931772 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Automated Self-Hypnosis
Description: Self-Hypnosis will be delivered through an interactive application administered through Amazon Alexa or Reveri.com.
Study NCT03425682 — intervention group
Intervention type: OTHER
Intervention: ViBone
Description: Viable Bone Allograft
Study NCT02613039 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Combined Estrogen-Progestin Oral Contraceptives
Description: All patients enrolled will undergo Combined Estrogen-Progestin Oral Contraceptives. Different compounds will be chosen according to the approved indications and clinical practice. Therefore it is not possible to provide a specific trade and/or generic name.
Study NCT01306318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eperisone hydrochloride plus diclofenac sodium capsule
Description: Single dose of fixed dose capsule formulation of eperisone hydrochloride 50 mg plus diclofenac sodium 50 mg to be given in healthy volunteers in fasting conditions
Study NCT01306318 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: eperisone hydrochloride tablet and diclofenac sodium tablet
Description: Single dose of eperisone hydrochloride 50 mg as tablet formulation and diclofenac sodium 50 mg as tablet formulation to be given in healthy volunteers in fasting conditions
Study NCT03625635 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized food-based intervention
Description: Diet plans and recommendations will be based on the individual's nutritional status, symptoms and treatment side-effects, socioeconomic and cultural preferences; as well as the WCRF/AICR guidelines adapting 1.5g/kg/d of dietary protein and when required, a caloric restriction (500-1000 kcal/d). Garlic and cruciferous vegetables will be encouraged as well as 5-9 servings of fruits and vegetables a day. The program will be based on the macronutrient meal-equivalent menu method, and standard food servings will be based on the Mexican Food Equivalent System. Breast cancer patients follow-up will be every 2-weeks and a different diet menu will be provided in each session by a specialized dietitian, unto 6-mo are completed.
Study NCT00283855 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online Self-Management
Description: Online Self-Management
Study NCT03937401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin infusion during MRI-HIFU treatment
Study NCT01672749 — intervention group
Intervention type: DEVICE
Intervention: Growth guiding construct using TROLLEY system
Description: Growth guiding construct using the DePuy Synthes TROLLEY Gliding Vehicles (GVs)
Study NCT01672749 — intervention group
Intervention type: DEVICE
Intervention: Spine based dual growing rod or rib based VEPTR
Description: spine based dual growing rod or the rib based Vertical Expandable Prosthetic Titanium Rib (VEPTR, Synthes North America)
Study NCT00288600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Immunoglobulin
Description: Intravenous Immunoglobulin
Study NCT00288600 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline solution
Description: Normal saline solution 10 ml/Kg
Study NCT01277653 — intervention group
Intervention type: DEVICE
Intervention: tumor maker interval shortly
Description: tumor maker interval every 3 month
Study NCT03806699 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile normal saline
Study NCT03806699 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ID93+GLA-SE
Description: ID93 is a recombinant protein antigen comprising 4 antigens from Mycobacterium tuberculosis (Mtb). The adjuvant GLA-SE is a TLR4 agonist in a stable oil-in-water emulsion.
Study NCT02723903 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Deanxit
Description: we use Deanxit for the patient with anxiety
Study NCT02723903 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Prozac
Description: we use Prozac for the patient with depression
Study NCT02723903 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: coronary artery disease treatment
Description: including medication, coronary artery stent implantation according to the severity of stenosis of the coronary arteries
Study NCT02688062 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeuroRegen Scaffold with BMMCs transplantation
Description: Patients with chronic SCI (ASIA grade A) will receive NeuroRegen Scaffold with bone marrow mononuclear cells (BMMCs) transplantation after localized scars cleared and after surgery patients will undergo a comprehensive rehabilitation, psychological and nutritional measures.
Study NCT02688062 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical intradural decompression and adhesiolysis
Description: Patients with chronic SCI (ASIA grade A) will receive intradural decompression and adhesiolysis surgery and after surgery patients will undergo a comprehensive rehabilitation, psychological and nutritional measures.
Study NCT04183153 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Participants will receive repetitive transcranial magnetic stimulation (rTMS) to determine if stimulating areas with activating functional connectivity will activate the hypothalamus and in turn, have a measurable effect on hormone levels.
Study NCT02984163 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise sessions will include a combination of aerobic, resistance, balance, and flexibility exercises delivered in a circuit-type class setting or group personal training format.
Study NCT03461419 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microcannula Harvest Adipose Stroma
Description: Use of Disposable, Closed Syringe Microcannula Harvest Autologous Adipose Stroma and Stem/Stromal Cells
Study NCT03461419 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Centricyte 1000
Description: Centricyte 1000 closed system digestion of stromal vascular fraction to isolate and concentrate stem/stromal cells associated with microvasculature
Study NCT03461419 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sterile Normal Saline IV Deployment of cSVF
Description: Sterile Normal Saline Suspension cSVF in 500 cc for Intravenous Delivery Including 150 micron in-line filtration
Study NCT02510105 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VDR4 ventilator (Intrapulmonary Percussive Ventilation)
Study NCT02510105 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CT scan
Study NCT02510105 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Servo-i
Study NCT02510105 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: - Intubation